<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32441">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684344</url>
  </required_header>
  <id_info>
    <org_study_id>59730</org_study_id>
    <nct_id>NCT02684344</nct_id>
  </id_info>
  <brief_title>Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention</brief_title>
  <official_title>Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized open-label study will be comprised of 2 cohorts: one control group and one
      treatment group. The trial will be conducted as an open label randomized trial to evaluate
      the efficacy of tamsulosin in the prevention of post-operative urinary retention. The study
      will include pre- and post-surgical evaluations of patients including symptoms of urinary
      retention and any adverse effects contributable to the study medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative urinary retention rate</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Post-Operative Urinary Retention</condition>
  <arm_group>
    <arm_group_label>Tamsulosin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive:
0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery
education about signs and symptoms of urinary retention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Education Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive:
1) education about signs and symptoms of urinary retention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Tamsulosin may have prophylactic properties against post-operative urinary retention</description>
    <arm_group_label>Tamsulosin Group</arm_group_label>
    <other_name>Flomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Education</intervention_name>
    <description>Education about signs and symptoms of urinary retention</description>
    <arm_group_label>Tamsulosin Group</arm_group_label>
    <arm_group_label>Education Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any male age 40 or older

          -  Scheduled to undergo one of the planned surgeries (thoracic, general, or urologic)

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Current use of alpha blocker

          -  Current use of a strong CYP 3A4 inhibitors

          -  Any allergy to tamsulosin, alpha-blocker medication class, or anaphylaxis allergy to
             sulfate containing medications

          -  Patients with any upcoming surgery for cataracts

          -  Currently enrolled in a clinical trial

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E. Messing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward E. Messing, MD</last_name>
    <phone>585-275-0998</phone>
    <email>edward_messing@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Nelson, MD</last_name>
    <phone>585-275-3343</phone>
    <email>benjamin_nelson@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward E. Messing, MD</last_name>
      <phone>585-275-0998</phone>
      <email>edward_messing@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin Nelson, MD</last_name>
      <phone>585-275-3343</phone>
      <email>benjamin_nelson@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 12, 2017</lastchanged_date>
  <firstreceived_date>February 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Edward Messing</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Post-Operative Urinary Retention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
